ArticleRadiation oncology (London, England)2025
Optimizing stereotactic ablative body radiotherapy for ultra-central lung lesions: a comparative dosimetric analysis.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systematic gravity-induced posterior tumour drift in free-breathing lung stereotactic ablative radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Partially Ablative Radiotherapy for Bulky Tumors: A Narrative Review of a Developing Concept.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundStereotactic ablative body radiotherapy (SABR) for ultra-central (UC) lung tumors is still challenging due to potentially severe complications caused by overdoses to critical mediastinal structures. This study aimed to compare the dosimetric advantages between volumetric modulated arc therapy (VMAT)-SABR and Helical Tomotherapy (HT)-SABR in UC lung lesions.
methodsFrom August 14, 2019, to June 4, 2023, patients with ultra-central (UC) lung tumors who received SABR for lung tumors were enrolled in this study. Two different radiotherapy plans were created based on the CT datasets of each case on the Eclipse and Tomotherapy treatment planning systems respectively. All patients received 60 Gy in 8 fractions. The parameters for dose evaluation of the target volumes and organs at risk (OARs) were compared based on the data extracted from dose-volume histograms. All of the statistical analyses were performed with SPSS 17.0 software.
resultsCompared with HT-SABR, VMAT-SABR significantly increased the Dmean of the iGTV (p = 0.002) and the Dmean, D10%, and D5% of the PTV (p = 0.000, 0.000, and 0.002, respectively). The values of D2cm, 95% isodose volume, and GI of VMAT-SABR significantly decreased by 15.11%, 7.78%, and 20.65% (p = 0.000; 0.000; 0.000) respectively. The values of Dmax of the spinal cord, spinal cord + 3 mm, esophagus, heart, trachea, proximal bronchial tree (Pbtree), and great vessels, and Dmean of the Non-GTV Lung and ipsilateral Non-GTV Lung with VMAT-SABR were significantly lower than those of HT-SABR.
conclusionOur study revealed that VMAT-SABR showed a steeper dose falloff and lower dose of the OARs. VMAT-SABR is a potentially optimal modality to improve the therapeutic ratio compared to HT-SABR in patients with UC lung lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.